Works matching AU Wysham, Carol H.

Results: 23

Day‐to‐day fasting self‐monitored blood glucose variability is associated with risk of hypoglycaemia in insulin‐treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials.

Published in:

Diabetes, Obesity & Metabolism, 2019, v. 21, n. 3, p. 622, doi. 10.1111/dom.13565

By:

DeVries, J. Hans;
Bailey, Timothy S.;
Bhargava, Anuj;
Gerety, Gregg;
Gumprecht, Janusz;
Heller, Simon;
Lane, Wendy;
Wysham, Carol H.;
Zinman, Bernard;
Bak, Britta A.;
Hachmann‐Nielsen, Elise;
Philis‐Tsimikas, Athena

Publication type:

Article

Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice‐daily basal insulin to once‐daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).

Published in:

Diabetes, Obesity & Metabolism, 2018, v. 20, n. 2, p. 448, doi. 10.1111/dom.13071

By:

Roussel, Ronan;
d'Emden, Michael C.;
Fisher, Miles;
Ampudia‐Blasco, F. Javier;
Stella, Peter;
Bizet, Florence;
Cali, Anna M. G.;
Wysham, Carol H.

Publication type:

Article

Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.

Published in:

Diabetes, Obesity & Metabolism, 2018, v. 20, n. 1, p. 165, doi. 10.1111/dom.13056

By:

Wysham, Carol H.;
Rosenstock, Julio;
Vetter, Marion L.;
Dong, Fang;
Öhman, Peter;
Iqbal, Nayyar

Publication type:

Article

Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 Trial.

Published in:

Clinical Diabetes, 2019, v. 37, n. 1, p. 73, doi. 10.2337/cd18-0016

By:

Chaykin, Louis;
Bhargava, Anuj;
de la Rosa, Raymond;
Wysham, Carol H.;
Troelsen, Lone Nørgård;
Østoft, Signe H.;
Philis-Tsimikas, Athena

Publication type:

Article

Safety and Efficacy of Insulin Degludec/ Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications.

Published in:

Clinical Diabetes, 2018, v. 36, n. 2, p. 149, doi. 10.2337/cd17-0064

By:

Wysham, Carol H.;
Campos, Carlos;
Kruger, Davida

Publication type:

Article

Consensus Report: Diabetes Performance Measures: Current Status and Future Directions.

Published in:

2011

By:

O'Connor, Patrick J.;
Bodkin, Noni L.;
Fradkin, Judith;
Glasgow, Russell E.;
Greenfield, Sheldon;
Gregg, Edward;
Kerr, Eve A.;
Pawlson, L. Gregory;
Selby, Joseph V.;
Sutherland, John E.;
Taylor, Michael L.;
Wysham, Carol H.

Publication type:

Journal Article

Consensus Report: Diabetes Performance Measures: Current Status and Future Directions.

Published in:

Clinical Diabetes, 2011, v. 29, n. 3, p. 102, doi. 10.2337/diaclin.29.3.102

By:

O'Connor, Patrick J.;
Bodkin, Noni L.;
Fradkin, Judith;
Glasgow, Russell E.;
Greenfield, Sheldon;
Gregg, Edward;
Kerr, Eve A.;
Pawlson, L. Gregory;
Selby, Joseph V.;
Sutherland, John E.;
Taylor, Michael L.;
Wysham, Carol H.

Publication type:

Article

Update on Insulin Management in Type 2 Diabetes.

Published in:

Diabetes Spectrum, 2009, v. 22, n. 2, p. 85, doi. 10.2337/diaspect.22.2.85

By:

Neumiller, Joshua J.;
Wysham, Carol H.;
Odegard, Peggy Soule

Publication type:

Article

Efficacy and Safety of Multiple Doses of Exenatide Once-Monthly Suspension in Patients With Type 2 Diabetes: A Phase II Randomized Clinical Trial.

Published in:

2016

By:

Wysham, Carol H.;
MacConell, Leigh;
Hardy, Elise

Publication type:

journal article

Practical Considerations for Initiating and Utilizing Flash Continuous Glucose Monitoring in Clinical Practice.

Published in:

Journal of the Endocrine Society, 2021, v. 5, n. 9, p. 1, doi. 10.1210/jendso/bvab064

By:

Wysham, Carol H;
Kruger, Davida F

Publication type:

Article

Differentiating Among the SGLT-2 Inhibitors: Considering Cardiovascular and Other Safety Outcomes.

Published in:

2018

By:

Miller, Eden M.;
Wysham, Carol H.

Publication type:

journal article

Diabetes Performance Measures: Current Status and Future Directions.

Published in:

Diabetes Care, 2011, v. 34, n. 7, p. 1651, doi. 10.2337/dc11-0735

By:

O'CONNOR, PATRICK J.;
BODKIN, NONI L.;
FRADKIN, JUDITH;
GLASGOW, RUSSELL E.;
GREENFIELD, SHELDON;
GREGG, EDWARD;
KERR, EVE A.;
PAWLSON, L. GREGORY;
SELBY, JOSEPH V.;
SUTHERLAND, JOHN E.;
TAYLOR, MICHAEL L.;
WYSHAM, CAROL H.

Publication type:

Article

Development of risk models for major adverse chronic renal outcomes among patients with type 2 diabetes mellitus using insurance claims: a retrospective observational study.

Published in:

2020

By:

Wysham, Carol H.;
Gauthier-Loiselle, Marjolaine;
Bailey, Robert A.;
Manceur, Ameur M.;
Lefebvre, Patrick;
Greenberg, Morris;
Duh, Mei Sheng;
Young, James B.

Publication type:

journal article

What's New in the Evolving Management of Type 2 Diabetes: Individualizing Therapy with Novel Treatment Options.

Published in:

Journal of Managed Care Medicine, 2018, v. 21, n. 4, p. 47

By:

Wysham, Carol H.

Publication type:

Article

Practical Guidance on Effective Basal Insulin Titration for Primary Care Providers.

Published in:

Clinical Diabetes, 2019, v. 37, n. 4, p. 368, doi. 10.2337/cd18-0091

By:

Kuritzky, Louis;
Reid, Timothy S.;
Wysham, Carol H.

Publication type:

Article

Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting.

Published in:

2018

By:

Wysham, Carol H.;
Pilon, Dominic;
Ingham, Mike;
Lafeuille, Marie-Hélène;
Emond, Bruno;
Kamstra, Rhiannon;
Pfeifer, Michael;
Lefebvre, Patrick

Publication type:

journal article

GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.

Published in:

Postgraduate Medicine, 2020, v. 132, p. 3, doi. 10.1080/00325481.2020.1798099

By:

Brunton, Stephen A.;
Wysham, Carol H.

Publication type:

Article

Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis.

Published in:

2017

By:

Wysham, Carol H.;
Lin, Jay;
Kuritzky, Louis

Publication type:

journal article

Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes.

Published in:

2016

By:

Oster, Gerry;
Sullivan, Sean D.;
Dalal, Mehul R.;
Kazemi, Mahmood R.;
Rojeski, Maria;
Wysham, Carol H.;
Sung, Jennifer;
Johnstone, Bryan;
Cali, Anna M.G.;
Wei, L.J.;
Traylor, Louise;
Anhalt, Henry;
Hull, Michelle;
Van Vleet, John;
Meneghini, Luigi F.

Publication type:

journal article

100-OR: ADA Presidents' Select Abstract: Efficacy and Safety of Once-Weekly Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist vs. Placebo as Monotherapy in People with Type 2 Diabetes (SURPASS-1).

Published in:

Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-100-OR

By:

ROSENSTOCK, JULIO;
WYSHAM, CAROL H.;
FRIAS, JUAN P.;
KANEKO, SHIZUKA;
LEE, CLARE;
LANDO, LAURA FERNANDEZ;
MAO, HUZHANG;
CUI, XUEWEI;
THIEU, VIVIAN

Publication type:

Article

1206-P: Effects of Canagliflozin (CANA) on Initiation of Insulin in CANVAS Program.

Published in:

Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1206-P

By:

MATTHEWS, DAVID R.;
WYSHAM, CAROL H.;
DAVIES, MELANIE J.;
SLEE, APRIL;
ALBA, MARIA;
LEE, MARY;
CAPUANO, GEORGE;
PERKOVIC, VLADO;
MAHAFFEY, KENNETH W.;
NEAL, BRUCE

Publication type:

Article

Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data.

Published in:

Cardiovascular Diabetology, 2018, v. 17, n. 1, p. N.PAG, doi. 10.1186/s12933-018-0759-z

By:

Young, James B.;
Gauthier-Loiselle, Marjolaine;
Bailey, Robert A.;
Manceur, Ameur M.;
Lefebvre, Patrick;
Greenberg, Morris;
Lafeuille, Marie-Hélène;
Duh, Mei Sheng;
Bookhart, Brahim;
Wysham, Carol H.

Publication type:

Article

Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.

Published in:

BMC Endocrine Disorders, 2017, v. 17, p. 1, doi. 10.1186/s12902-017-0180-8

By:

Wysham, Carol H.;
Lefebvre, Patrick;
Pilon, Dominic;
Ingham, Mike;
Lafeuille, Marie-Hélène;
Emond, Bruno;
Kamstra, Rhiannon;
Chow, Wing;
Pfeifer, Michael;
Mei Sheng Duh

Publication type:

Article